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Hereditary pulmonary alveolar proteinosis (PAP) caused by mutations in CSF2RA or CSF2RB, which
encode GM-CSF receptor a and b respectively, is a rare disease. Although some experimental therapeutic
strategies have been proposed, no clinical evidence has yet been reported. We herein describe the clinical
course and recurrence of hereditary PAP after lung transplantation. A 36-year-old woman developed PAP
of unknown etiology. She underwent bilateral lung transplantation from living donors at the age of 42
years because of severe respiratory failure complicated by pulmonary ﬁbrosis. However, PAP recurred
after 9 months, and we found that donor-origin alveolar macrophages had been almost completely
replaced with recipient-origin macrophages. We performed a genetic analysis and identiﬁed a point
deletion in the CSF2RB gene that caused a GM-CSF receptor-mediated signaling defect. PAP progressed
with ﬁbrosis in both transplanted lungs, and the patient died of respiratory failure 5 years after the lung
transplantation. Distinct from recent reports on pulmonary macrophage transplantation in mice, this
case suggests that human alveolar macrophages might not maintain their population only by self-
renewal but may depend on a supply of precursor cells from the circulation. Bone marrow trans-
plantation should be considered for treatment of severe PAP with GM-CSF receptor gene deﬁciency.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pulmonary alveolar proteinosis (PAP) is a rare disease charac-
terized by abnormal accumulation of surfactant within alveoli and
terminal bronchioli, and this surfactant interferes with gas ex-
change [1]. About 90% of patients with PAP have autoimmune PAP
(aPAP), in which autoantibodies against granulocyte-macrophage
colony stimulating factor (GM-CSF) inhibit the differentiation of
alveolar macrophages, causing impaired surfactant clearance.eolar proteinosis; hPAP, he-
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Ltd. This is an open access article uHereditary and unclassiﬁed PAP account for less than 1% in adult
PAP [2]. Of these cases, genetic aberration of the GM-CSF receptor
has been rarely reported [3e6]. Whole-lung lavage is only palliative
and symptomatic, but it remains the only option currently avail-
able. Some experimental therapeutic strategies have been proposed
for hereditary PAP (hPAP); however, these treatments are not ready
for practical application [6,7].
Most cases of aPAP can be successfully treated by whole-lung
lavage and/or GM-CSF inhalation therapy. Therefore, patients
with PAP are not generally candidates for lung transplantation. We
previously described a patient with unclassiﬁed PAP who under-
went bilateral lung transplantation from living donors for rescue
from rapidly progressing respiratory failure complicated by pul-
monary ﬁbrosis [8]. Several months after that lung transplantation,
we identiﬁed a nonsense mutation in CSF2RB in this patient andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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PAP after this lung transplantation and discuss its mechanism.2. Case report
The above-described 36-year-old woman noticed dyspnea on
exertion and was diagnosed with PAP. Despite repeatedwhole-lung
lavage and GM-CSF inhalation therapy, her respiratory condition
had become critical 6 years after the onset of PAP. After deliberate
consideration, she underwent bilateral lung transplantation with
right and left lungs from her husband and brother, respectively [8].
At the time of transplantation, the etiology of PAP was unknown
other than negativity for serum GM-CSF autoantibodies.
After lung transplantation, she was treated with tacrolimus,
mycophenolate mofetil, and prednisolone. Nine months after the
transplantation, she developed mild dyspnea and ground glass
opacity that predominantly progressed in the left lung (Fig. 1).
Sixteen months after the lung transplantation, we obtained bron-
choalveolar lavage ﬂuid from the bilateral lungs and found bilateral
recurrence of PAP (Fig. 2A and B). Fluorescence in situ hybridization
(FISH) analysis demonstrated that more than 99% of the alveolar
macrophages from both lungs did not harbor the Y chromosome,
indicating that the phenotype of the alveolar macrophages had
reversed to the recipient type in the bilateral lungs (Fig. 2C).
The recurrence of PAP and replacement of donor-origin alveolar
macrophages led us to intensively investigate gene abnormalities
because the patient was suspected to have functional defects in
alveolar macrophages that are known to be derived from bone
marrow. Consequently, we found a homozygous one-point deletion
in the CSF2RB gene with an intracellular STAT5 signaling defect as
reported previously [3]. We thoroughly discussed the feasibility of
bone marrow transplantation with hematologists but could not
obtain their consent to perform such an operation. We informed
the patient about the risks and beneﬁts and determined not to
perform bone marrow transplantation. This decision was based on
the fact that the patient had already received transplants from two
different donors and had several serious risk factors for a poor
prognosis in receiving bone marrow transplantation, such as
reactivated hepatitis B virus infection, renal dysfunction, respira-
tory dysfunction, and having received immunosuppressive therapy
after the lung transplantation.
Thereafter, she underwent whole-lung lavages ﬁve times andFig. 1. High-resolution computed tomographic appearance of the chest 31 months
after transplantation. The crazy paving appearance is consistent with recurrence of
pulmonary alveolar proteinosis, and left dominance was seen from the beginning of
recurrence.twice for the left and right lungs, respectively, during the 4 years
post-transplantation. She gradually developed respiratory failure
with progression of PAP, then required home oxygen therapy.
Furthermore, 4 years after the lung transplantation, her forced
expiratory volume in 1 s (FEV1.0) decreased from 1.95 to 1.13 L for 3
months. Based on the clinical diagnosis of bronchiolitis obliterans
syndrome without donor-speciﬁc human leukocyte antigen anti-
bodies, we started two courses of steroid pulse therapy and
increased immunosuppressants. Even though she inhaled prophy-
lactic amphotericin B, she developed new multiple nodular
shadows and elevation of 1,3-b-d-glucan and galactomannan an-
tigen. Aspergillus fumigatus, Aspergillus terreus, and Aspergillus ﬂa-
vus were cultured from bronchoalveolar lavage, and we started
intensive antifungal therapy for invasive pulmonary aspergillosis.
Although nodular shadows shrank and her condition transiently
stabilized, she gradually deteriorated. Unfortunately, she eventu-
ally died of respiratory failure due to PAP recurrence and progres-
sion to bronchiolitis obliterans syndrome.
Autopsy showed recurrence of PAP accompanied by focal
ﬁbrosis. In accordance with computed tomography ﬁndings, path-
ological PAP ﬁndings were also predominant in the left lung. Pul-
monary emphysemawas seen only in the right lung (Fig. 3A and B).
Chronic airway rejection, which was pathologically detected as
bronchiolitis obliterans, and chronic vascular rejection with C4d
deposition conﬁrmed by immunohistochemistry were also found.
(Fig. 3C and D). Furthermore, Aspergillus infection remained in both
lungs despite intensive antifungal therapy (Fig. 4A and B). The GM-
CSF common b receptor was not expressed on alveolar macro-
phages but on hyperplastic alveolar epithelial cells in the bilateral
lungs (Fig. 4C and D).
3. Discussion
In this case report, we describe the outcome of lung trans-
plantation in a patient with hPAP caused by deﬁcient expression of
the GM-CSF receptor common b subunit. As stated above, this gene
defect was identiﬁed after the lung transplantation; therefore, a
poor outcome was attained. Our decision to perform lung trans-
plantation at that time was inevitable and surely contributed to
prolonging the patient's life. However, because some hPAP cases
have been recently reported [3e6], hPAP screening should be per-
formed in patients with unclassiﬁed PAP, even adults, so that the
feasibility of bone marrow transplantation can be discussed in the
early stage of disease progression. One case of idiopathic PAP
recurrence after lung transplantation was reported in the 1990s,
although the etiology of the PAP was not clearly described [9].
The present case provides direct evidence that alveolar macro-
phages of donor origin replaced cells of recipient origin after lung
transplantation. Although the origin of resident alveolar macro-
phages is still controversial, the leading hypothesis in the “steady
state” indicates that resident alveolar macrophages are predomi-
nantly maintained by replication of local alveolar macrophages
independent of circulating monocytes entering the lung [10]. A
recent study has demonstrated that transplanted alveolar macro-
phages can maintain their population for a long period by local
replication [7]. These ﬁndings raise the possibility of curative
treatment option for hPAP by lung transplantation; however, the
outcome of our casewas otherwise unfortunate. In contrast, several
studies have demonstrated that monocytes of bone marrow origin
in chimeric mice replace alveolar macrophages after bone marrow
transplantation [11,12]. Furthermore, replacement of alveolar
macrophages by bone marrow-derived donor-origin cells has been
reported in both lung and bone marrow transplantations [13,14].
This controversymight be explained by the assumption that lung or
bone marrow transplantation itself alters the “steady state” of the
Fig. 2. Results of bronchoscopic analysis. (A) Bronchoalveolar lavage cells showing foamy alveolar macrophages (Diff-Quik stain). (B) Snapshot image of foamy alveolar macrophages
under a scanning electron microscope. (C) FISH analysis demonstrated that 99% of the alveolar macrophages had XX sex chromosomes.
Fig. 3. Histological examination of autopsied lungs. (A) The right lung, donated by the husband, and (B) the left lung, donated by the brother, showed accumulation of surfactant
proteins (hematoxylin and eosin stain). (C) Chronic airway rejection that manifested as bronchiolitis obliterans was histologically conﬁrmed (Elastica van Gieson stain). (D) Chronic
vascular rejection was conﬁrmed by C4d deposition on vascular endothelial cells (immunohistochemical stain).
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cially immunosuppressive agents, are usually used. These agents
can directly affect bone marrow and production of cytokines.
Furthermore, immunosuppressive therapy could affect the function
of alveolar macrophages and cause PAP after lung transplantation
[15]. The interference of “steady state” after lung transplantation
with several of the above-mentioned factors might allowreplacement of alveolar macrophages by donor-origin cells. This
hypothesis is consistent with the fact that the alveolar macro-
phages in this case study were almost completely replaced 16
months after the lung transplantation. Therefore, bone marrow
transplantation might have been the most appropriate therapeutic
option for this case of PAP [7]. Pulmonary macrophage trans-
plantation therapy, which was recently reported in GM-CSF
Fig. 4. Histological examination of autopsied lungs. (A, B) Granulomas and Aspergillus were detected (hematoxylin and eosin stain and Grocott’s methenamine silver stain).
Immunohistochemical analysis showed expression of the GM-CSF common b receptor in right lung (C) and left lung (D) epithelial cells (arrow), but not alveolar macrophages
(arrowhead).
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future [6].
The laterality of recurrence was notable in our case. The fact that
the sibling's lung (not the husband's lung) was predominantly
affected pathologically and radiologically after transplantation in-
dicates the possible involvement of GM-CSF receptor b chain
expression in the lung parenchyma. However, immunohistochem-
ical analysis of alveolar epithelial cells showed at least the
expression of the GM-CSF b receptor chain in the parenchyma of
both lungs. Although we did not have a chance to perform genetic
analysis on the blood from the sibling donor, the possibility of a
heterozygous abnormality in the CSF2RB gene in her sibling re-
mains. Alternatively, the right lung donated from her husband, an
ex-smoker, showed emphysematous change that may have atten-
uated the disease expression.4. Conclusion
Lung transplantation to treat hPAP due to an abnormality of the
GM-CSF receptor resulted in recurrence of PAP after 9 months. We
demonstrated that alveolar macrophages were almost completely
replaced by cells of recipient origin by at least 16 months after lung
transplantation. Lung transplantation itself in this case contributed
to prolongation of the patient's life and was a necessary interven-
tion at that time. Importantly, this case indicates that GM-CSF re-
ceptor analysis should be performed in cases of unclassiﬁed PAP to
detect hPAP so that early consideration of bone marrow trans-
plantation can be discussed in the treatment of hPAP.Disclosures
The authors declare that there is no conﬂict of interest regarding
the publication of this paper.Acknowledgements
We thank Mr. Akitoyo Ichinose for performing the electron
microscopic examination. We also thank SRL, Inc. for performing
the FISH analysis.
This report was partly supported by a grant, “Rare lung diseases
(pulmonary alveolar proteinosis, congenital interstitial lung disease
and hereditary hemorrhagic telangiectasia) {H24-Nanchitou(Nan-
chi)-Ippan-035},” from the Ministry of Health, Labour and Welfare,
Japan.References
[1] B.C. Trapnell, J.A. Whitsett, K. Nakata, Pulmonary alveolar proteinosis, N. Engl.
J. Med. 349 (2003) 2527e2539.
[2] H. Ishii, J.F. Seymour, R. Tazawa, Y. Inoue, N. Uchida, A. Nishida, et al., Sec-
ondary pulmonary alveolar proteinosis complicating myelodysplastic syn-
drome results in worsening of prognosis: a retrospective cohort study in
Japan, BMC Pulm. Med. 14 (2014) 37.
[3] T. Tanaka, N. Motoi, Y. Tsuchihashi, R. Tazawa, C. Kaneko, T. Nei, et al., Adult-
onset hereditary pulmonary alveolar proteinosis caused by a single-base
deletion in CSF2RB, J. Med. Genet. 48 (2011) 205e209.
[4] T. Suzuki, B. Maranda, T. Sakagami, P. Catellier, C.Y. Couture, B.C. Carey, et al.,
Hereditary pulmonary alveolar proteinosis caused by recessive CSF2RB mu-
tations, Eur. Respir. J. 37 (2011) 201e204.
[5] T. Suzuki, T. Sakagami, B.K. Rubin, L.M. Nogee, R.E. Wood, S.L. Zimmerman, et
al., Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA,
J. Exp. Med. 205 (2008) 2703e2710.
[6] T. Suzuki, T. Sakagami, L.R. Young, B.C. Carey, R.E. Wood, M. Luisetti, et al.,
Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation,
diagnosis, and therapy, Am. J. Respir. Crit. Care Med. 182 (2010) 1292e1304.
[7] T. Suzuki, P. Arumugam, T. Sakagami, N. Lachmann, C. Chalk, A. Sallese, et al.,
Pulmonary macrophage transplantation therapy, Nature 514 (2014) 450e454.
[8] T. Tagawa, N. Yamasaki, T. Tsuchiya, T. Miyazaki, K. Matsuki, Y. Tsuchihashi, et
al., Living-donor lobar lung transplantation for pulmonary alveolar proteinosis
in an adult: report of a case, Surg. Today 41 (2011) 1142e1144.
[9] L.A. Parker, D.B. Novotny, Recurrent alveolar proteinosis following double lung
transplantation, Chest 111 (1997) 1457e1458.
[10] D. Hashimoto, A. Chow, C. Noizat, P. Teo, M.B. Beasley, M. Leboeuf, et al.,
Tissue-resident macrophages self-maintain locally throughout adult life with
minimal contribution from circulating monocytes, Immunity 38 (2013)
792e804.
[11] U.A. Maus, S. Janzen, G. Wall, M. Srivastava, T.S. Blackwell, J.W. Christman, et
M. Takaki et al. / Respiratory Medicine Case Reports 19 (2016) 89e93 93al., Resident alveolar macrophages are replaced by recruited monocytes in
response to endotoxin-induced lung inﬂammation, Am. J. Respir. Cell Mol.
Biol. 35 (2006) 227e235.
[12] J. Murphy, R. Summer, A.A. Wilson, D.N. Kotton, A. Fine, The prolonged life-
span of alveolar macrophages, Am. J. Respir. Cell Mol. Biol. 38 (2008)
380e385.
[13] E.D. Thomas, R.E. Ramberg, G.E. Sale, R.S. Sparkes, D.W. Golde, Direct evidence
for a bone marrow origin of the alveolar macrophage in man, Science 192(1976) 1016e1018.
[14] K. Nakata, H. Gotoh, J. Watanabe, T. Uetake, I. Komuro, K. Yuasa, et al.,
Augmented proliferation of human alveolar macrophages after allogeneic
bone marrow transplantation, Blood 93 (1999) 667e673.
[15] A.A. Gal, J.A. Bryan, K.R. Kanter, E.C. Lawrence, Cytopathology of pulmonary
alveolar proteinosis complicating lung transplantation, J. Heart Lung Transpl.
23 (2004) 135e138.
